Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Net Operating Profit After Tax (NOPAT) 5 year CAGR for the quarter ending December 31, 2023

Third Harmonic Bio Inc. Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the quarter ending December 31, 2023. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Third Harmonic Bio Inc. Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -15,814,659.33, a -103.17% change year over year.
Third Harmonic Bio Inc. Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -7,783,998.84.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends